Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof

• US 8,574,613 B2
• Filed: 01/19/2010
• Issued: 11/05/2013
• Est. Priority Date: 04/26/2000
• Status: Expired due to Fees

• Current Assignee: EyePoint Pharmaceuticals, Inc.
• Original Assignee: pSivida US, Inc
• Inventors: Guo, Hong, Ashton, Paul
• Primary Examiner(s): FISHER, ABIGAIL L
• Application Number:
  US12/689,956
• Publication Number:
  US 20100119580A1
• Time in Patent Office: 1,386 Days
• Field of Search: 424/423, 424/422, 424/427, 424/400, 424/424
• US Class Current: 424/423
• CPC Class Codes: A61F 9/0017 implantable in, or in contact with, the eye, e.g. ocular inserts
• CPC Class Codes: A61K 31/58 containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin digitoxin A61K31/7048
• CPC Class Codes: A61K 9/0051 Ocular inserts, ocular implants
• CPC Class Codes: A61K 9/0092 Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
• CPC Class Codes: A61K 9/20 Pills, tablets, discs, rods A61K9/0004, A61K9/0007, A61K9/0056, A61K9/0065 take precedence; for reconstitution of a drink A61K9/0095
• CPC Class Codes: A61K 9/5089 Processes
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 9/12 Antihypertensives
• CPC Class Codes: Y10T 29/49888 Subsequently coating

Abstract

A method and device for treating a mammalian organism to obtain a desired local or systemic physiological or pharmacological effect is provided. The method includes administering a sustained release drug delivery system to a mammalian organism in need of such treatment at an area wherein release of an effective agent is desired and allowing the effective agent to pass through the device in a controlled manner. The device includes an inner core or reservoir including the effective agent, an impermeable tube which encloses portions of the reservoir, and a permeable member at an end of the tube.

Claims

1. A sustained release drug delivery system comprising:

a drug reservoir comprising a therapeutically effective amount of an agent;

an inner tube having first and second open ends and covering at least a portion of said drug reservoir, wherein said inner tube is impermeable to the passage of the agent, dimensionally stable and capable of supporting its own weight; and

an outer layer, permeable to the passage of said agent, covering only a portion of said inner tube,

wherein, upon implantation, agent is released through at least one of the open ends.

2. A sustained release drug delivery system in accordance with claim 1, wherein said inner tube includes at least one port or hole.

3. A sustained release drug delivery system in accordance with claim 1, further comprising an impermeable member positioned at said inner tube first open end.

4. A sustained release drug delivery system in accordance with claim 1, further comprising a permeable member positioned at said inner tube first open end.

5. A sustained release drug delivery system in accordance with claim 4, further comprising a permeable member positioned at said inner tube second open end.

6. A sustained release drug delivery system in accordance with claim 1, wherein said outer layer includes at least one port or hole.

7. A sustained release drug delivery system in accordance with claim 1, wherein the inner tube is formed of a material selected from ethyl vinyl acetate, polyvinyl acetate, cross-linked polyvinyl alcohol, cross-linked polyvinyl butyrate, ethylene ethylacrylate copolymer, polyethyl hexylacrylate, polyvinyl chloride, polyvinyl acetals, plasticized ethylene vinylacetate copolymer, polyvinyl alcohol, polyvinyl acetate, ethylene vinylchloride copolymer, polyvinyl esters, polyvinylbutyrate, polyvinylformal, polyamides, polymethylmethacrylate, polybutyl methacrylate, plasticized polyvinyl chloride, plasticized nylon, plasticized soft nylon, plasticized polyethylene terephthalate, natural rubber, polyisoprene, polyisobutylene, polybutadiene, polyethylene, polytetrafluoroethylene, polyvinylidene chloride, polyacrylonitrile, cross-linked polyvinylpyrrolidone, polytrifluorochloroethylene, chlorinated polyethylene, poly(1,4′

-isopropylidene diphenylene carbonate), vinylidene chloride, acrylonitrile copolymer, vinyl chloride-diethyl fumarate copolymer, silicone rubbers, ethylene-propylene rubber, silicone-carbonate copolymers, vinylidene chloride-vinyl chloride copolymer, vinyl chloride-acrylonitrile copolymer, and vinylidene chloride-acrylonitrile copolymer.

8. A sustained release drug delivery system in accordance with claim 1, wherein the outer layer is formed of a material selected from ethyl vinyl acetate, polyvinyl acetate, cross-linked polyvinyl alcohol, cross-linked polyvinyl butyrate, ethylene ethylacrylate copolymer, polyethyl hexylacrylate, polyvinyl chloride, polyvinyl acetals, plasticized ethylene vinylacetate copolymer, polyvinyl alcohol, polyvinyl acetate, ethylene vinylchloride copolymer, polyvinyl esters, polyvinylbutyrate, polyvinylformal, polyamides, polymethylmethacrylate, polybutyl methacrylate, plasticized polyvinyl chloride, plasticized nylon, plasticized soft nylon, plasticized polyethylene terephthalate, natural rubber, polyisoprene, polyisobutylene, polybutadiene, polyethylene, polytetrafluoroethylene, polyvinylidene chloride, polyacrylonitrile, cross-linked polyvinylpyrrolidone, polytrifluorochloroethylene, chlorinated polyethylene, poly(1,4′

-isopropylidene diphenylene carbonate), vinylidene chloride, acrylonitrile copolymer, vinyl chloride-diethyl fumarate copolymer, silicone rubbers, ethylene-propylene rubber, silicone-carbonate copolymers, vinylidene chloride-vinyl chloride copolymer, vinyl chloride-acrylonitrile copolymer, and vinylidene chloride-acrylonitrile copolymer.

9. A sustained release drug delivery system in accordance with claim 1, wherein the agent is selected from anesthetics, anti-cancer agents, anti-inflammatory agents, anti-fungal agents, anti-viral agents, cell transport/mobility impending agents, antiglaucoma drugs, immunological response modifiers, peptides and proteins, growth hormones, steroidal compounds, corticosteroids, carbonic anhydrase inhibitors, neuroprotectants, antibiotics, antibacterial agents, antiallergenics, decongestants, miotics and anti-cholinesterase, mydriatics, sympathomimetics, and prodrugs.

10. A sustained release drug delivery system in accordance with claim 1, wherein the agent is selected from lidocaine, benzodiazepam, 5-fluorouracil, adriamycin, 6-mannose phosphate, fluconazole, trisodium phosphomonoformate, trifluorothymidine, acyclovir, ganciclovir, DDI, DDC, AZT, colchicine, vincristine, cytochalasin B, timolol, betaxol, atenalol, muramyl dipeptide, cyclosporin, insulin, insulin related growth factor, nimodipine, tetracycline, chlortetracycline, bacitracin, neomycin, polymyxin, gramicidin, oxytetracycline, chloramphenicol, gentamycin, erythromycin, sulfonamides, sulfacetamide, sulfamethizole, sulfisoxazole, idoxuridine, nitrofurazone, sodium propionate, antazoline, methapyriline, chlorpheniramine, pyrilamine, prophenpyridamine, hydrocortisone, hydrocortisone acetate, dexamethasone 21-phosphate, dexamethasone, prednisolone, fluocinolone acetonide, fluocinolone, medrysone, methylprednisolone, prednisolone 21-phosphate, prednisolone acetate, fluoromethalone, betamethasone, triminolone, phenylephrine, naphazoline, tetrahydrazoline, pilocarpine, eserine salicylate, carbachol, di-isopropyl fluorophosphate, phospholine iodine, demecarium bromide, atropine sulfate, cyclopentolate, homatropine, scopolamine, tropicamide, eucatropine, hydroxyamphetamine, epinephrine, and salts thereof.

11. A sustained release drug delivery system in accordance with claim 9, wherein the agent is an anti-viral agent.

12. A sustained release drug delivery system in accordance with claim 11, wherein the agent is selected from trisodium phosphomonoformate, trifluorothymidine, acyclovir, ganciclovir, DDI, DDC, AZT, idoxuridine, and salts thereof.

13. A sustained release drug delivery system of claim 1, wherein the inner tube is dimensionally stable such that the diffusion area does not change more than 50% from the diffusion rate expected based on the chemical potential gradient across the drug delivery system.

14. A sustained release drug delivery system of claim 1, wherein the outer layer covers the first and second open ends.

17. A sustained release drug delivery system in accordance with claim 10, wherein the agent is fluocinolone acetonide.

15. A sustained release drug delivery system consisting of:

a drug reservoir comprising a therapeutically effective amount of an agent;

an inner tube having first and second open ends and covering at least a portion of said drug reservoir, wherein said inner tube is impermeable to the passage of the agent, wherein said inner tube is dimensionally stable and capable of supporting its own weight;

an impermeable member at said first open end of the inner tube; and

an outer layer, permeable to the passage of said agent, covering only a portion of said inner tube,

wherein, upon implantation, agent is released through the second open end.

16. An injectable sustained release drug delivery system comprising:

a drug reservoir comprising a therapeutically effective amount of an agent;

an inner tube having first and second open ends and covering at least a portion of said drug reservoir, wherein said inner tube is impermeable to the passage of the agent, dimensionally stable and capable of supporting its own weight; and

an outer layer, permeable to the passage of said agent, covering the first and second open ends but only a portion of said drug reservoir and/or inner tube,

wherein, upon implantation, agent is released through at least one of the open ends.